YWHAE is a novel interaction partner of Helicobacter pylori CagA

Xiaoyan Zhang1,2, Bangwei Zeng1,2,3, Chunyan Wen1,2

  • 1Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, 1 Xuefu North Road, University Town, Fuzhou, Fujian Province 350122, PR China.

FEMS Microbiology Letters
|November 7, 2017
PubMed

Insights

Helicobacter pylori CagA protein interacts with YWHAE, enhancing NF-κB activation. This CagA-YWHAE interaction offers new insights into H. pylori-induced gastric cancer development.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Oncology

Background:

  • Helicobacter pylori CagA is a key virulence factor implicated in gastric diseases.
  • The precise molecular mechanisms linking CagA to gastric cancer remain incompletely understood.

Purpose of the Study:

  • To identify host proteins interacting with CagA.
  • To elucidate the role of CagA-host protein interactions in NF-κB signaling and gastric tumorigenesis.

Main Methods:

  • GAL4 yeast two-hybrid system for screening CagA-interacting proteins.
  • In vitro (GST pull-down) and in vivo (immunolocalization, co-immunoprecipitation) assays to validate interactions.
  • Cell-based assays (overexpression, knockdown) to assess NF-κB activation.

Main Results:

  • Identified YWHAE (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon) as a CagA-interacting protein.
  • Confirmed CagA-YWHAE interaction in vitro and in vivo.
  • Demonstrated that YWHAE mediates CagA-induced NF-κB activation; YWHAE overexpression enhanced it, while knockdown inhibited it.

Conclusions:

  • CagA enhances YWHAE-mediated transactivation of NF-κB.
  • This interaction provides a novel molecular mechanism contributing to H. pylori-associated gastric cancer.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.5K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
905
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.0K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.3K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
548